Home › Multiple Myeloma › Michigan
Pag-aaral pangklinika para sa Multiple Myeloma sa Michigan
26 pag-aaral para sa Multiple Myeloma ang naghahanap ng mga kalahok sa mga site sa Michigan.
Mga Lungsod sa Michigan
- Detroit19 pag-aaral
- Ann Arbor10 pag-aaral
- Grand Rapids8 pag-aaral
- Warren4 pag-aaral
- Lansing4 pag-aaral
- Livonia3 pag-aaral
- Saginaw3 pag-aaral
- Flint3 pag-aaral
- Waterford3 pag-aaral
Opisyal na teksto ng pag-aaral (English)
A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)
- START Midwest /ID# 279035, Grand Rapids
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 29, 2026 · NCT07409246A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
- Barbara Ann Karmanos Cancer Institute - Detroit, Detroit
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT07393282A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- University of Michigan, Ann Arbor
- Henry Ford Cancer - Detroit Brigitte Harris Cancer Pavilion, Detroit
- Cancer And Hematology Centers of Western Michigan PC, Grand Rapids
- at 2 pa
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT05552222A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
- University of Michigan Health System, Ann Arbor
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT04634552A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Karmanos Cancer Institute, Detroit
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT07518186A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
- Barbara Ann Karmanos Cancer Institute, Detroit
Nagre-recruitPhase 4
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT05201781TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- Trinity Health Ann Arbor Hospital, Ann Arbor
- Henry Ford Health Saint John Hospital, Detroit
- Genesys Hurley Cancer Institute, Flint
- at 7 pa
Nagre-recruitPhase 2
Edad 12 pataas · Lahat ng kasarian · Na-update Set 22, 2026 · NCT02693535A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
- University of Michigan Health System - Ann Arbor /ID# 271536, Ann Arbor
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 14, 2026 · NCT06953960A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
- Henry Ford Health System, Detroit
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 9, 2026 · NCT06980480AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
- Research Site, Ann Arbor
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 19, 2026 · NCT06106945Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
- MyMichigan Medical Center Gratiot, Alma
- MyMichigan Medical Center Alpena, Alpena
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- at 36 pa
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 19, 2026 · NCT04566328A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
- GSK Investigational Site, Grand Rapids
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 19, 2026 · NCT05714839A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
- Karmanos Cancer Institute, Detroit
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 18, 2026 · NCT06292780AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
- Research Site, Ann Arbor
- Research Site, Detroit
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 17, 2026 · NCT05850234Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
- Research Site, Detroit
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 14, 2026 · NCT07764978A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
- START Midwest, Grand Rapids
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 12, 2026 · NCT07280013A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
- Karmanos Cancer Institute, Detroit
- START Midwest, Grand Rapids
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 6, 2026 · NCT07284758A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
- Karmanos Cancer Institute, Detroit
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 8, 2026 · NCT05137054Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
- University of Michigan, Ann Arbor
- Henry Ford Cancer - Detroit (Brigitte Harris Cancer Pavilion), Detroit
Nagre-recruitPhase 4
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 1, 2026 · NCT06057402Iberdomide and Daratumumab as Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple Myeloma
- Karmanos Cancer Institute, Detroit
- KCI at McLaren Greater Lansing, Lansing
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 26, 2026 · NCT06107738Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
- Saint Joseph Mercy Hospital, Ann Arbor
- Bronson Battle Creek, Battle Creek
- Saint Joseph Mercy Brighton, Brighton
- at 51 pa
Nagre-recruitPhase 3
Lahat ng edad · Lahat ng kasarian · Na-update Hun 10, 2026 · NCT05561387Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
- Henry Ford St. John Hospital, Grosse Pointe Woods
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 4, 2026 · NCT05243797Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
- Karmanos Cancer Institute, Detroit
- START Midwest, Grand Rapids
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update May 19, 2026 · NCT06433947A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
- Karmanos Cancer Institute, Detroit
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update May 13, 2026 · NCT05828511A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
- GSK Investigational Site, Ann Arbor
- GSK Investigational Site, Detroit
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Abr 22, 2026 · NCT06679101Addressing Social Determinants of Health Among Metro Detroit Cancer Survivors
- Karmanos Cancer Institute, Detroit
Nagre-recruit
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 26, 2025 · NCT06908629Mula sa ClinicalTrials.gov, na-kuha noong Okt 1, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.